Litifilimab Advances CLE Treatment With Positive Phase 2 Data

Key Takeaways

• Litifilimab demonstrated statistically significant improvements across CLE endpoints in the Phase 2 AMETHYST study, with early separation from placebo.
• A substantial unmet need persists in CLE because of the lack of FDA-approved therapies and limitations of current systemic treatments.
• A targeted BDCA2 mechanism and encouraging early efficacy support continued development, though long-term data remain essential.

Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythematosus (CLE), meeting primary and key secondary endpoints.

CLE remains an area of significant unmet need, according to Joseph F. Merola, MD, MMSc, because of a lack of US Food and Drug Administration (FDA)-approved therapies.

“The unmet need is high,” Dr. Merola told Practical Dermatology. “The disease state is quite a high burden for patients.”

He added that many patients are refractory to standard therapies and that commonly used agents, including methotrexate, mycophenolate, and thalidomide analogs, present safety and tolerability challenges, particularly in women of reproductive age.

AMETHYST (NCT05531565) is a randomized, double-blind, placebo-controlled Phase 2/3 study evaluating subcutaneous litifilimab every 4 weeks in patients with active chronic and/or subacute CLE. Among 93 participants in Part A, baseline disease severity was balanced (mean CLASI-A: 19.4 placebo vs 20.2 litifilimab).

At Week 16, 14.7% of patients receiving litifilimab achieved a CLA-IGA-R erythema score of 0–1 compared with 2.9% on placebo (P < .05), increasing to 19.0% vs 4.2% at Week 24 (P < .05). Secondary endpoints also favored litifilimab, including CLASI-50 (40.8% vs 21.0%, P < .05), CLASI-70 (21.7% vs 5.8%, P < .05), and CLASI-A 0–3 (16.3% vs 0.0%, P < .01). Separation between groups was observed as early as Week 4.

Dr. Merola emphasized both the mechanistic rationale and clinical relevance of these findings.

“Plasmacytoid dendritic cells are highly relevant to the disease state, and central to the pathogenesis of disease is type I interferon,” he said. “Where the rubber meets the road is the efficacy. We are seeing this improvement in mucocutaneous disease, which means we’re on the right track.” 

Dr. Merola also noted that the trial design represents progress for the field.

“We have not really had a lot of studies that are properly designed for a cutaneous lupus population, so this group should be very proud that they have designed a proper cutaneous lupus trial,” he said, highlighting the inclusion of well-characterized patients with moderate-to-severe CLE. 

Dr. Merola said the efficacy signals aligned with expectations.

“We saw upward of 40% of patients achieving CLASI 50, with approximately 20% achieving a CLASI 70 response and an IGA 0/1 response,” he said. “For the first set of drugs in this space, to me, this is highly encouraging.” 

Litifilimab was well tolerated, with safety findings consistent with prior studies, including in patients receiving background immunosuppressive therapy.

“The safety tolerability is highly reassuring,” Dr. Merola noted, adding that combination use may reflect real-world practice. 

Looking ahead, he emphasized the importance of durability and broader disease impact.

“We want to evaluate maintenance of responde and see if we continue to gain efficacy over time,” he said. “It will be important for us to understand how this drug fits in other domains of disease, including systemic lupus erythematosus.”